NO316073B1 - Isolert peptid, anvendelse derav, nukleinsyresekvens, terapeutisk sammensetning, fremgangsmåte for utforming av peptid og fremgangsmåte for åbestemme i individer tilstedev¶relse av immunoglobulin spesifikt for etproteinantigen - Google Patents

Isolert peptid, anvendelse derav, nukleinsyresekvens, terapeutisk sammensetning, fremgangsmåte for utforming av peptid og fremgangsmåte for åbestemme i individer tilstedev¶relse av immunoglobulin spesifikt for etproteinantigen Download PDF

Info

Publication number: NO316073B1
Authority: NO; Norway
Prior art keywords: peptide; protein; regions; antigen; cell
Prior art date: 1991-10-16

Application number

NO19941370A

Other languages

English (en)

Norwegian (no)

Other versions

NO941370L (no

NO941370D0 (no

Inventor

Bruce L Rogers

Jay P Morgenstern

Julian F Bond

Richard D Garman

Mei-Chang Kuo

Malcolm Morville

Julia Greenstein

Original Assignee

Immulogic Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-16

Filing date

1994-04-15

Publication date

2003-12-08

1991-12-13 Priority claimed from US07/807,529 external-priority patent/US5547669A/en

1994-04-15 Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp

1994-04-15 Publication of NO941370D0 publication Critical patent/NO941370D0/no

1994-06-08 Publication of NO941370L publication Critical patent/NO941370L/no

2003-12-08 Publication of NO316073B1 publication Critical patent/NO316073B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 447
108091007433 antigens Proteins 0.000 title claims abstract description 162
102000036639 antigens Human genes 0.000 title claims abstract description 162
238000000034 method Methods 0.000 title claims abstract description 54
239000000203 mixture Substances 0.000 title claims abstract description 29
230000001225 therapeutic effect Effects 0.000 title claims abstract description 19
108060003951 Immunoglobulin Proteins 0.000 title claims description 33
102000018358 immunoglobulin Human genes 0.000 title claims description 33
150000007523 nucleic acids Chemical group 0.000 title claims description 17
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 14
230000015572 biosynthetic process Effects 0.000 title description 18
108090000623 proteins and genes Proteins 0.000 claims abstract description 211
102000004169 proteins and genes Human genes 0.000 claims abstract description 205
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 202
239000013566 allergen Substances 0.000 claims abstract description 199
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 157
230000004936 stimulating effect Effects 0.000 claims abstract description 40
230000035945 sensitivity Effects 0.000 claims abstract description 19
239000000427 antigen Substances 0.000 claims description 67
230000027455 binding Effects 0.000 claims description 42
101710117971 Peptide Y Proteins 0.000 claims description 26
101710188315 Protein X Proteins 0.000 claims description 24
125000003275 alpha amino acid group Chemical group 0.000 claims description 24
150000001413 amino acids Chemical class 0.000 claims description 21
230000000694 effects Effects 0.000 claims description 19
208000026935 allergic disease Diseases 0.000 claims description 16
230000000638 stimulation Effects 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 14
210000004369 blood Anatomy 0.000 claims description 11
239000008280 blood Substances 0.000 claims description 11
210000003630 histaminocyte Anatomy 0.000 claims description 11
108010091748 peptide A Proteins 0.000 claims description 11
101800005149 Peptide B Proteins 0.000 claims description 10
208000010668 atopic eczema Diseases 0.000 claims description 10
239000003085 diluting agent Substances 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
239000012503 blood component Substances 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
241000238710 Dermatophagoides Species 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
108010005636 polypeptide C Proteins 0.000 claims description 7
230000000172 allergic effect Effects 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
235000003826 Artemisia Nutrition 0.000 claims description 4
235000003261 Artemisia vulgaris Nutrition 0.000 claims description 4
241000219429 Betula Species 0.000 claims description 4
235000003932 Betula Nutrition 0.000 claims description 4
241000219495 Betulaceae Species 0.000 claims description 4
241000238658 Blattella Species 0.000 claims description 4
244000281762 Chenopodium ambrosioides Species 0.000 claims description 4
235000000509 Chenopodium ambrosioides Nutrition 0.000 claims description 4
235000005490 Chenopodium botrys Nutrition 0.000 claims description 4
241000795633 Olea <sea slug> Species 0.000 claims description 4
241001127637 Plantago Species 0.000 claims description 4
241000219492 Quercus Species 0.000 claims description 4
244000030166 artemisia Species 0.000 claims description 4
235000009052 artemisia Nutrition 0.000 claims description 4
210000003651 basophil Anatomy 0.000 claims description 4
230000000295 complement effect Effects 0.000 claims description 4
241000238740 Dermatophagoides pteronyssinus Species 0.000 claims description 3
108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 claims description 3
230000001419 dependent effect Effects 0.000 claims description 3
108091005573 modified proteins Proteins 0.000 claims description 3
102000035118 modified proteins Human genes 0.000 claims description 3
241000282465 Canis Species 0.000 claims description 2
108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
241000894007 species Species 0.000 claims description 2
241000223600 Alternaria Species 0.000 claims 2
241000218692 Cryptomeria Species 0.000 claims 2
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
241000282324 Felis Species 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
238000002483 medication Methods 0.000 claims 1
230000002797 proteolythic effect Effects 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 156
125000000539 amino acid group Chemical group 0.000 description 56
238000003752 polymerase chain reaction Methods 0.000 description 42
210000004027 cell Anatomy 0.000 description 36
108020004414 DNA Proteins 0.000 description 32
230000004044 response Effects 0.000 description 27
235000001014 amino acid Nutrition 0.000 description 19
238000010276 construction Methods 0.000 description 19
230000009257 reactivity Effects 0.000 description 19
238000006243 chemical reaction Methods 0.000 description 18
238000012360 testing method Methods 0.000 description 18
108091034117 Oligonucleotide Proteins 0.000 description 17
239000000523 sample Substances 0.000 description 13
208000027930 type IV hypersensitivity disease Diseases 0.000 description 13
206010020751 Hypersensitivity Diseases 0.000 description 12
230000005867 T cell response Effects 0.000 description 12
206010045240 Type I hypersensitivity Diseases 0.000 description 12
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
238000003776 cleavage reaction Methods 0.000 description 12
230000007017 scission Effects 0.000 description 12
239000000243 solution Substances 0.000 description 12
208000010216 atopic IgE responsiveness Diseases 0.000 description 11
208000006313 Delayed Hypersensitivity Diseases 0.000 description 10
208000001718 Immediate Hypersensitivity Diseases 0.000 description 10
230000007815 allergy Effects 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
230000014509 gene expression Effects 0.000 description 10
108090000190 Thrombin Proteins 0.000 description 9
239000012634 fragment Substances 0.000 description 9
229960004072 thrombin Drugs 0.000 description 9
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
239000012980 RPMI-1640 medium Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
238000002474 experimental method Methods 0.000 description 7
239000000499 gel Substances 0.000 description 7
230000028993 immune response Effects 0.000 description 7
108020004705 Codon Proteins 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
210000001165 lymph node Anatomy 0.000 description 6
201000006417 multiple sclerosis Diseases 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
239000013615 primer Substances 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000010366 cell biology technique Methods 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
238000011534 incubation Methods 0.000 description 5
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
241000282326 Felis catus Species 0.000 description 4
108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 4
102100037681 Protein FEV Human genes 0.000 description 4
101710198166 Protein FEV Proteins 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
210000000612 antigen-presenting cell Anatomy 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
229960001340 histamine Drugs 0.000 description 4
238000013507 mapping Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000000284 resting effect Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
229920000936 Agarose Polymers 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
108010058846 Ovalbumin Proteins 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000003455 anaphylaxis Diseases 0.000 description 3
239000007621 bhi medium Substances 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
230000029087 digestion Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000428 dust Substances 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
108010021083 hen egg lysozyme Proteins 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
229940092253 ovalbumin Drugs 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000013598 vector Substances 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
244000036975 Ambrosia artemisiifolia Species 0.000 description 2
235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 2
206010002198 Anaphylactic reaction Diseases 0.000 description 2
241000256836 Apis Species 0.000 description 2
206010003645 Atopy Diseases 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
241000701867 Enterobacteria phage T7 Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
102000008214 Glutamate decarboxylase Human genes 0.000 description 2
108091022930 Glutamate decarboxylase Proteins 0.000 description 2
101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
101710137500 T7 RNA polymerase Proteins 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
239000003513 alkali Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000036783 anaphylactic response Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000002585 base Substances 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000000306 component Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
229960002743 glutamine Drugs 0.000 description 2
125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
102000054064 human MBP Human genes 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000005567 liquid scintillation counting Methods 0.000 description 2
108091005601 modified peptides Proteins 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
229940046166 oligodeoxynucleotide Drugs 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
235000020030 perry Nutrition 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
125000006853 reporter group Chemical group 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
230000009466 transformation Effects 0.000 description 2
PZEUTLIKVUEDLB-UHFFFAOYSA-N 2-[[[2-[[6-amino-2-[[2-[[6-amino-2-[[2-[[2-[[2-[[2-[[2-[2-[[1-[2-[[2-[[2-[[2-[[2-[[2-[[6-amino-2-[[2-[[2-[2-[[2-[[2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]acetyl]amino]propanoylamino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]propanoylamino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(carbamoylamino)propanoyl]-(3-amino-3-oxopropyl)carbamoyl]amino]pentanediamide Chemical compound CCC(C)C(NC(=O)CN)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CNC(N)=O)C(=O)N(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O PZEUTLIKVUEDLB-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108700031361 Brachyury Proteins 0.000 description 1
108090000007 Carboxypeptidase M Proteins 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
240000005109 Cryptomeria japonica Species 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010055622 Dermatophagoides farinae antigen f 1 Proteins 0.000 description 1
101001116419 Dermatophagoides pteronyssinus Peptidase 1 Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010049466 Erythroblastosis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
241000209082 Lolium Species 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
101710118538 Protease Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
240000006694 Stellaria media Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000017274 T cell anergy Effects 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
238000000137 annealing Methods 0.000 description 1
235000003484 annual ragweed Nutrition 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
239000003659 bee venom Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000006263 bur ragweed Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
239000012707 chemical precursor Substances 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000001297 coherence probe microscopy Methods 0.000 description 1
235000003488 common ragweed Nutrition 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
229940124736 hepatitis-B vaccine Drugs 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
229940066369 honey bee venom Drugs 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000000178 monomer Substances 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
230000008447 perception Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000009736 ragweed Nutrition 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000012552 review Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
230000001810 trypsinlike Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
-1 use thereof Proteins 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Insects & Arthropods (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pathology (AREA)
Pulmonology (AREA)
Botany (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Analytical Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)

NO19941370A 1991-10-16 1994-04-15 Isolert peptid, anvendelse derav, nukleinsyresekvens, terapeutisk sammensetning, fremgangsmåte for utforming av peptid og fremgangsmåte for åbestemme i individer tilstedev¶relse av immunoglobulin spesifikt for etproteinantigen NO316073B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US77785991A	1991-10-16	1991-10-16
US07/807,529 US5547669A (en)	1989-11-03	1991-12-13	Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
PCT/US1992/008694 WO1993008280A1 (en)	1991-10-16	1992-10-16	Recombitope peptides

Publications (3)

Publication Number	Publication Date
NO941370D0 NO941370D0 (no)	1994-04-15
NO941370L NO941370L (no)	1994-06-08
NO316073B1 true NO316073B1 (no)	2003-12-08

Family

ID=27119373

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19941370A NO316073B1 (no)	1991-10-16	1994-04-15	Isolert peptid, anvendelse derav, nukleinsyresekvens, terapeutisk sammensetning, fremgangsmåte for utforming av peptid og fremgangsmåte for åbestemme i individer tilstedev¶relse av immunoglobulin spesifikt for etproteinantigen

Country Status (15)

Country	Link
EP (1)	EP0610335B1 (fi)
JP (1)	JP4246794B2 (fi)
KR (1)	KR100271417B1 (fi)
AT (1)	ATE382699T1 (fi)
AU (1)	AU682658B2 (fi)
CA (1)	CA2121498C (fi)
DK (1)	DK0610335T3 (fi)
ES (1)	ES2300100T3 (fi)
FI (1)	FI109809B (fi)
HU (1)	HU227959B1 (fi)
IL (1)	IL103456A (fi)
NO (1)	NO316073B1 (fi)
NZ (2)	NZ244782A (fi)
PT (1)	PT100978B (fi)
WO (1)	WO1993008280A1 (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6019972A (en) *	1989-11-03	2000-02-01	Immulogic Pharmaceutical Corporation	Peptides of human T cell reactive feline protein (TRFP)
US6120769A (en) *	1989-11-03	2000-09-19	Immulogic Pharmaceutical Corporation	Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
IL105153A (en) *	1992-03-25	1999-12-22	Immulogic Pharma Corp	Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US6759234B1 (en) *	1994-09-02	2004-07-06	Immulogic Pharmaceutical Corporation	Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
US6719976B1 (en)	1996-03-10	2004-04-13	Meiji Milk Products Co., Ltd.	Peptide-based immunotherapeutic agent for treating allergic diseases
CA2247009C (en) *	1996-03-21	2009-08-04	Imperial College Of Science, Technology And Medicine	Cryptic peptides and method for their identification
JP3945822B2 (ja) *	1996-05-24	2007-07-18	カイロンコーポレイション	複数エピトープ融合タンパク質
US6514731B1 (en)	1996-05-24	2003-02-04	Chiron Corporation	Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
US7112329B1 (en)	1996-06-14	2006-09-26	Meiji Milk Products Co. Ltd.	T cell epitope peptide
JP4176750B2 (ja) *	1996-06-14	2008-11-05	明治乳業株式会社	Ｔ細胞エピトープペプチド
IL132611A0 (en)	1999-10-27	2001-03-19	Yeda Res & Dev	Synthetic genes and polypeptides and pharmaceutical compositions comprising them
AUPQ776100A0 (en)	2000-05-26	2000-06-15	Australian National University, The	Synthetic molecules and uses therefor
EP1221317A1 (en)	2000-12-28	2002-07-10	SHAN-Beteiligungsgesellschaft m.b.H.	Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
ES2247433T3 (es) *	2003-01-21	2006-03-01	Biomay Produktions- Und Handels- Aktiengesellschaft	Procedimiento para la preparacion de proteinas de mosaico hipoalergenicas.
AT503690A1 (de) *	2006-06-09	2007-12-15	Biomay Ag	Hypoallergene moleküle
GB2455108A (en) *	2007-11-28	2009-06-03	Circassia Ltd	T-Cell dependent method for detecting non-allergic or intrinsic disorders
JP2017507906A (ja)	2013-12-23	2017-03-23	アルク−アベーロアクティーゼルスカブ	塵ダニアレルギーの処置におけるペプチド組合せおよびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2013359A6 (es) *	1988-11-04	1990-05-01	Corporacion Biolog Farmaceutic	Procedimiento para la fabricacion de alergenos inmunogenicos polimerizados.
JP3251012B2 (ja) *	1989-11-03	2002-01-28	イミユロジク・フアーマシユーチカル・コーポレーシヨン	室内塵から単離したヒトｔ細胞反応性猫蛋白質（ｔｒｆｐ）及びその利用
KR100274321B1 (ko) *	1990-09-11	2000-12-15	스미드 이. 그레이엄	데르마토파고이디즈(집 먼지 진드기)의 알레르기 항원의 클로닝 및 서열결정

1992
- 1992-10-16 WO PCT/US1992/008694 patent/WO1993008280A1/en active IP Right Grant
- 1992-10-16 DK DK92922494T patent/DK0610335T3/da active
- 1992-10-16 CA CA002121498A patent/CA2121498C/en not_active Expired - Lifetime
- 1992-10-16 KR KR1019940701294A patent/KR100271417B1/ko not_active IP Right Cessation
- 1992-10-16 NZ NZ244782A patent/NZ244782A/en not_active IP Right Cessation
- 1992-10-16 ES ES92922494T patent/ES2300100T3/es not_active Expired - Lifetime
- 1992-10-16 IL IL103456A patent/IL103456A/en not_active IP Right Cessation
- 1992-10-16 AT AT92922494T patent/ATE382699T1/de active
- 1992-10-16 NZ NZ299122A patent/NZ299122A/en not_active IP Right Cessation
- 1992-10-16 AU AU27940/92A patent/AU682658B2/en not_active Expired
- 1992-10-16 EP EP92922494A patent/EP0610335B1/en not_active Expired - Lifetime
- 1992-10-16 HU HU9401109A patent/HU227959B1/hu unknown
- 1992-10-16 JP JP50774893A patent/JP4246794B2/ja not_active Expired - Lifetime
- 1992-10-16 PT PT100978A patent/PT100978B/pt not_active IP Right Cessation
1994
- 1994-04-15 NO NO19941370A patent/NO316073B1/no not_active IP Right Cessation
- 1994-04-15 FI FI941758A patent/FI109809B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL103456A0 (en)	1993-03-15
CA2121498A1 (en)	1993-04-29
JP4246794B2 (ja)	2009-04-02
HU9401109D0 (en)	1994-07-28
NO941370L (no)	1994-06-08
AU682658B2 (en)	1997-10-16
KR100271417B1 (ko)	2000-12-01
NZ299122A (en)	2005-02-25
PT100978A (pt)	1994-01-31
FI109809B (fi)	2002-10-15
NZ244782A (en)	1996-12-20
CA2121498C (en)	2009-02-17
EP0610335A1 (en)	1994-08-17
DK0610335T3 (da)	2008-04-28
FI941758A (fi)	1994-06-16
AU2794092A (en)	1993-05-21
HU227959B1 (en)	2012-07-30
WO1993008280A1 (en)	1993-04-29
NO941370D0 (no)	1994-04-15
JPH07503362A (ja)	1995-04-13
FI941758A0 (fi)	1994-04-15
HUT70263A (en)	1995-09-28
ES2300100T3 (es)	2008-06-01
EP0610335B1 (en)	2008-01-02
ATE382699T1 (de)	2008-01-15
PT100978B (pt)	1999-10-29
IL103456A (en)	2006-06-11

Publication	Publication Date	Title
US5547669A (en)	1996-08-20	Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
Himly et al.	2003	Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin‐like and a hydroxyproline‐rich domain
NO316073B1 (no)	2003-12-08	Isolert peptid, anvendelse derav, nukleinsyresekvens, terapeutisk sammensetning, fremgangsmåte for utforming av peptid og fremgangsmåte for åbestemme i individer tilstedev¶relse av immunoglobulin spesifikt for etproteinantigen
US5820862A (en)	1998-10-13	T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JP2009005709A (ja)	2009-01-15	ダーマトファゴイデス（家ほこりダニ）からの主要なアレルゲンのｔ細胞エピトープの製造方法
US6120769A (en)	2000-09-19	Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US6413738B1 (en)	2002-07-02	House dust mite allergen, Der f VII, and uses therefor
US6048962A (en)	2000-04-11	Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US7288256B1 (en)	2007-10-30	T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JPH09502346A (ja)	1997-03-11	自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
AU3922693A (en)	1993-10-21	Peptides useful for inducing tolerance
NO317850B1 (no)	2004-12-20	Isolert nukleinsyre som koder for Der p III-proteinallergen,isolert Der p III proteinallergen, farmasoytisk blanding omfattende allergenet, samt anvendelse derav for fremstilling av farmasoytisk blanding og fremgangsmater for fremstilling av slike.
JP2001518451A (ja)	2001-10-16	アレルゲンの非アナフィラキシー形およびその使用
JP5432921B2 (ja)	2014-03-05	勃起不全を処置するための組成物および方法
NO316922B1 (no)	2004-06-28	Isolert peptid og nukleinsyre av proteinallergener fra Dermatophagoides (husstovmidd) samt anvendelse og terapeutisk sammensetning, og fremgangsmate for detektering av sensitiviteten overfor husstovmidd
CN113164573B (zh)	2024-05-31	包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法
DE69233720T2 (de)	2009-01-02	Verfahren zum Entwurf von Rekombitopen Peptiden

Legal Events

Date	Code	Title	Description
2006-12-11	CREP	Change of representative	Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO
2012-11-12	MK1K	Patent expired